Are only CD4+, CD8+ or both T cell types required for 3AC-induced tumor immunity and are these cells qualitatively changed by SHIPi to become more potent effector/memory cells or are their numbers simply increased by promoting their differentiation to T effector cells with enhanced survival in the tumor microenvironment. This evidence concerns the gene CD8A and neoplasm.